GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » 3-Year ROIIC %

TYPTF (Tryptamine Therapeutics) 3-Year ROIIC % : 2,784.21% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Tryptamine Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2023 was 2,784.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Tryptamine Therapeutics's 3-Year ROIIC % or its related term are showing as below:

TYPTF's 3-Year ROIIC % is ranked better than
97.94% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs TYPTF: 2784.21

Tryptamine Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Tryptamine Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics 3-Year ROIIC % Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
3-Year ROIIC %
Get a 7-Day Free Trial - - - -162.64 2,784.21

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -162.64 - 2,784.21 -

Competitive Comparison of Tryptamine Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Tryptamine Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's 3-Year ROIIC % falls into.



Tryptamine Therapeutics 3-Year ROIIC % Calculation

Tryptamine Therapeutics's 3-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -6.438 (Jun. 2023) - -5.524 (Jun. 2020) )/( 2.772 (Jun. 2023) - 2.89 (Jun. 2020) )
=-0.914/-0.118
=774.58%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Tryptamine Therapeutics  (OTCPK:TYPTF) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Tryptamine Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics Business Description

Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines